Objective:Longshengzhi capsule(LSZC)is an optimized preparation based on the traditional Chinese Medicine formula Buyanghuanwu Decoction(BYHWD),and is approved by the China Food and Drug Administration for treating st...Objective:Longshengzhi capsule(LSZC)is an optimized preparation based on the traditional Chinese Medicine formula Buyanghuanwu Decoction(BYHWD),and is approved by the China Food and Drug Administration for treating stroke-induced disability and vascular diseases.Herein,we examined the pharmacodynamics,anti-apoptotic and anti-oxidant actions,and potential mechanisms of action of LSZC following stroke in rats.Methods:Permanent middle cerebral artery occlusion(MCAO)was used as an ischemic stroke model.LSZC was administered intragastrically.We examined the survival rate,bodyweight,and neurological deficits in stroke rats.Brain infarct size was determined by 2,3,5-triphenyltetrazolium chloride staining.Brain pathology was examined using hematoxylin and eosin staining,Nissl staining,and TdT-mediated dUTP Nick-End Labeling staining.Malondialdehyde,catalase,superoxide dismutase,and glutathione levels were examined by commercial kits.Expression of Nrf2,heme oxygenase-1,Bax,Bcl-2,cleaved caspase-3,and caspase-3 proteins in brain tissue was measured by Western blot.Results:LSZC markedly improved the survival rate and bodyweight,and reduced infarct volume and neurological deficit scores,in MCAO stroke rats.LSZC also significantly attenuated oxidative stress,as indicated by decreased expression of malondialdehyde,and upregulation of Nrf2,heme oxygenase-1,catalase,superoxide dismutase,and glutathione.Moreover,LSZC significantly decreased apoptosis,including a decrease in Bax and cleaved caspase-3 expression,and an increase in Bcl-2,as well as a reduction in numbers of apoptotic neurons.Conclusion:LSZC treatment is neuroprotective against ischemic stroke,potentially via reducing oxidative stress and apoptosis.The Nrf2 and apoptotic signaling pathways may play important roles in the antioxidant and anti-apoptotic actions of LSZC.展开更多
Objective:To systematically evaluate the efficacy and safety of Longshengzhi Capsules(龙生蛭胶囊)in the treatment of cerebral infarction.Materials and methods:A randomized controlled trial of Longshengzhi Capsules(龙...Objective:To systematically evaluate the efficacy and safety of Longshengzhi Capsules(龙生蛭胶囊)in the treatment of cerebral infarction.Materials and methods:A randomized controlled trial of Longshengzhi Capsules(龙生蛭胶囊)for cerebral infarction was screened out by searching CNKI,Wanfang Data,VIP,Sino Med,Cochrane Library,Pub Med,Embase,Web of Science in a systematic way and was based on Handbook 5.1 evaluation criteria and tools and Rev Man 5.3 software for Meta-analysis of the final inclusion of the study.Results:A total of 12 studies were included,including 9 meta-analysis of studies and 3 other studies,with a total sample size of 1446 cases,including 746 cases in the experimental group and 700 cases in the control group.The results of Meta-analysis showed that the Chinese Stroke Chinical Neurological Deficit Scales Score(CSS)of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment alone(MD=–6.98,95%CI[–7.41,–6.55],P<0.00001).The National Institues of Health Sroke Scales(NIHSS)score of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment alone(MD=–1.49,95%CI[–1.78,–1.20],P<0.00001);The quality of life score of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment(MD=6.65,95%CI[3.97,9.33],P<0.00001).Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment in treating cerebral infarction was better than conventional treatment in Homocysteine(Hcy)(MD=–2.44,95%CI[–2.89,–1.99],P<0.00001).There was no significant difference in the incidence of adverse reactions between Longshengzhi Capsules(龙生蛭胶囊)and conventional treatment for cerebral infarction(RR=0.58,95%CI[0.31,1.06],P=0.08).The main adverse reactions were skin rash,gastrointestinal reaction,headache,dizziness,abdominal pain,irritability,chills,urticaria,blood pressure reduction,dyspnea,vomiting,fever and urinary tract infection,which did not affect the treatment.Due to the small sample size,a large sample is needed for further verification.Conclusion:Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction reduced CSS and NIHSS scores,improved quality of life scores,and reduced Hcy,without serious adverse reactions,and the incidence of adverse reactions was similar to that of conventional treatment.However,the quality of the study is not high,and it is necessary to improve the level of evidence quality by using clinical trial schemes with large samples,rigorous design and compliance with international standards.展开更多
Objective:To study the effects of Longshengzhi Capsules(龙生蛭胶囊,LSZC)against Parkinson’s disease based on network pharmacology and biological research.Parkinson’s disease(PD)is a kind of degenerative disease with...Objective:To study the effects of Longshengzhi Capsules(龙生蛭胶囊,LSZC)against Parkinson’s disease based on network pharmacology and biological research.Parkinson’s disease(PD)is a kind of degenerative disease with a complex pathological process.Up to date,there is still no effective clinical treatment to cure this condition.The poor prognosis seriously affects patients’quality of life.In the case of dealing with complex pathological processes conditions,the flexible therapy strategy from traditional Chinese medicine(TCM)has unique advantages.LSZC has been clinically approved for the treatment of arteriosclerotic cerebral infarction with symptoms of paraplegia,numbness,skewed mouth,and unfavorable speech.Methods:Active ingredients of LSZC were obtained from TCM systems pharmacology(TCMSP)database,Chinese Taiwan TCM database and Sym Map database.Therapeutic targets were predicted through Pubchem and Swiss Target Prediction databases.Parkinson-related targets were collected by the Comparative Toxicogenomics Database(CTD),TTD and Drug bank databases.The overlap targets of LSZC and PD were identified for pathway enrichment analysis by utilizing Gene Ontology(GO)and the Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analysis and the Cytoscape software was used to visualize the results.Then the potential pharmacological effects of LSZC on PD were further explored by using mice model induced by MPTP.Results:LSZC showed a regulation effect on the pathological process of PD and improving the symptoms of PD model animals in vivo.And the results also showed that different drug groups have different intervention pathways for PD,suggesting that LSZC intervention on PD may be achieved through multiple channels.Conclusion:LSZC has an intervention effect on the pathological process of PD,indicating that patients with PD may benefit from LSZC usage in clinical practice.展开更多
基金The authors thank Beijing University of Chinese Medicine for providing the necessary facilities and funding this project(No.2180071720034).
文摘Objective:Longshengzhi capsule(LSZC)is an optimized preparation based on the traditional Chinese Medicine formula Buyanghuanwu Decoction(BYHWD),and is approved by the China Food and Drug Administration for treating stroke-induced disability and vascular diseases.Herein,we examined the pharmacodynamics,anti-apoptotic and anti-oxidant actions,and potential mechanisms of action of LSZC following stroke in rats.Methods:Permanent middle cerebral artery occlusion(MCAO)was used as an ischemic stroke model.LSZC was administered intragastrically.We examined the survival rate,bodyweight,and neurological deficits in stroke rats.Brain infarct size was determined by 2,3,5-triphenyltetrazolium chloride staining.Brain pathology was examined using hematoxylin and eosin staining,Nissl staining,and TdT-mediated dUTP Nick-End Labeling staining.Malondialdehyde,catalase,superoxide dismutase,and glutathione levels were examined by commercial kits.Expression of Nrf2,heme oxygenase-1,Bax,Bcl-2,cleaved caspase-3,and caspase-3 proteins in brain tissue was measured by Western blot.Results:LSZC markedly improved the survival rate and bodyweight,and reduced infarct volume and neurological deficit scores,in MCAO stroke rats.LSZC also significantly attenuated oxidative stress,as indicated by decreased expression of malondialdehyde,and upregulation of Nrf2,heme oxygenase-1,catalase,superoxide dismutase,and glutathione.Moreover,LSZC significantly decreased apoptosis,including a decrease in Bax and cleaved caspase-3 expression,and an increase in Bcl-2,as well as a reduction in numbers of apoptotic neurons.Conclusion:LSZC treatment is neuroprotective against ischemic stroke,potentially via reducing oxidative stress and apoptosis.The Nrf2 and apoptotic signaling pathways may play important roles in the antioxidant and anti-apoptotic actions of LSZC.
基金The Ministry of Science and Technology,2018 National Key R&D Program"Research on Modernization of Traditional Chinese Medicine"project"Evidence-based evaluation of ten types of proprietary Chinese medicines and classic prescriptions for the treatment of major diseases after marketing and demonstration research on their effect mechanisms"(2018YFC1707400)。
文摘Objective:To systematically evaluate the efficacy and safety of Longshengzhi Capsules(龙生蛭胶囊)in the treatment of cerebral infarction.Materials and methods:A randomized controlled trial of Longshengzhi Capsules(龙生蛭胶囊)for cerebral infarction was screened out by searching CNKI,Wanfang Data,VIP,Sino Med,Cochrane Library,Pub Med,Embase,Web of Science in a systematic way and was based on Handbook 5.1 evaluation criteria and tools and Rev Man 5.3 software for Meta-analysis of the final inclusion of the study.Results:A total of 12 studies were included,including 9 meta-analysis of studies and 3 other studies,with a total sample size of 1446 cases,including 746 cases in the experimental group and 700 cases in the control group.The results of Meta-analysis showed that the Chinese Stroke Chinical Neurological Deficit Scales Score(CSS)of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment alone(MD=–6.98,95%CI[–7.41,–6.55],P<0.00001).The National Institues of Health Sroke Scales(NIHSS)score of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment alone(MD=–1.49,95%CI[–1.78,–1.20],P<0.00001);The quality of life score of Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction was better than that of conventional treatment(MD=6.65,95%CI[3.97,9.33],P<0.00001).Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment in treating cerebral infarction was better than conventional treatment in Homocysteine(Hcy)(MD=–2.44,95%CI[–2.89,–1.99],P<0.00001).There was no significant difference in the incidence of adverse reactions between Longshengzhi Capsules(龙生蛭胶囊)and conventional treatment for cerebral infarction(RR=0.58,95%CI[0.31,1.06],P=0.08).The main adverse reactions were skin rash,gastrointestinal reaction,headache,dizziness,abdominal pain,irritability,chills,urticaria,blood pressure reduction,dyspnea,vomiting,fever and urinary tract infection,which did not affect the treatment.Due to the small sample size,a large sample is needed for further verification.Conclusion:Longshengzhi Capsules(龙生蛭胶囊)combined with conventional treatment for cerebral infarction reduced CSS and NIHSS scores,improved quality of life scores,and reduced Hcy,without serious adverse reactions,and the incidence of adverse reactions was similar to that of conventional treatment.However,the quality of the study is not high,and it is necessary to improve the level of evidence quality by using clinical trial schemes with large samples,rigorous design and compliance with international standards.
基金The project(No.QS20211103)of Beijing City University"City Star Program"Training Program(NO.202111418015)of Beijing City University
文摘Objective:To study the effects of Longshengzhi Capsules(龙生蛭胶囊,LSZC)against Parkinson’s disease based on network pharmacology and biological research.Parkinson’s disease(PD)is a kind of degenerative disease with a complex pathological process.Up to date,there is still no effective clinical treatment to cure this condition.The poor prognosis seriously affects patients’quality of life.In the case of dealing with complex pathological processes conditions,the flexible therapy strategy from traditional Chinese medicine(TCM)has unique advantages.LSZC has been clinically approved for the treatment of arteriosclerotic cerebral infarction with symptoms of paraplegia,numbness,skewed mouth,and unfavorable speech.Methods:Active ingredients of LSZC were obtained from TCM systems pharmacology(TCMSP)database,Chinese Taiwan TCM database and Sym Map database.Therapeutic targets were predicted through Pubchem and Swiss Target Prediction databases.Parkinson-related targets were collected by the Comparative Toxicogenomics Database(CTD),TTD and Drug bank databases.The overlap targets of LSZC and PD were identified for pathway enrichment analysis by utilizing Gene Ontology(GO)and the Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analysis and the Cytoscape software was used to visualize the results.Then the potential pharmacological effects of LSZC on PD were further explored by using mice model induced by MPTP.Results:LSZC showed a regulation effect on the pathological process of PD and improving the symptoms of PD model animals in vivo.And the results also showed that different drug groups have different intervention pathways for PD,suggesting that LSZC intervention on PD may be achieved through multiple channels.Conclusion:LSZC has an intervention effect on the pathological process of PD,indicating that patients with PD may benefit from LSZC usage in clinical practice.
